Inactive/Delisted stock
Better Therapeutics Stock (NASDAQ:BTTX)
Previous Close
$NaN
52W Range
- - $0.24
50D Avg
-
200D Avg
-
Market Cap
$5.45K
Avg Vol (3M)
$29.07K
Beta
1.89
Div Yield
-
BTTX Company Profile
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
BTTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IKT | Inhibikase Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ABVC | ABVC BioPharma, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| SNTI | Senti Biosciences, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| HOOK | HOOKIPA Pharma Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| AVTE | Aerovate Therapeutics, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| CING | Cingulate Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| FBRX | Forte Biosciences, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |